![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
Departments of Biopharmaceutical Sciences (F.X., D.L.K.) and Pharmaceutical Chemistry (P.R.O.d.M., D.L.K.), University of California San Francisco, San Francisco, California; and Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas (J.R.F.)
Received for publication
September 8, 2003
Accepted
November 14, 2003.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
-hydroxylated to 20-hydroxyeicosatetraenoic acid (20-HETE), which has effects on vasoactivity and renal tubular transport and has been implicated in the regulation of blood pressure. Cytochrome P450 (P450) 4A isoforms are generally considered the major arachidonic acid -hydroxylases; however, little is known about the role of rat CYP4F isoforms in 20-HETE formation. The rat CYP4F isoforms, CYP4F1, CYP4F4, CYP4F5, and CYP4F6, were heterologously expressed in Escherichia coli, and their substrate specificity in fatty acid metabolism was characterized. Substrate-binding assays indicated that leukotriene B4 (LTB4) and arachidonic acid bound CYP4F1 and CYP4F4 in a type-I manner with a Ks of 25 to 59 µM, and lauric acid bound CYP4F4 poorly. Reconstituted CYP4F1 and CYP4F4 catalyzed the -hydroxylation of LTB4 with a Km of 24 and 31 µM, respectively, and CYP4F5 had minor activity in LTB4 metabolism. Importantly, CYP4F1 and CYP4F4 catalyzed the -hydroxylation of arachidonic acid with an apparent kcat of 9 and 11 min–1, respectively. Lauric acid was a poor substrate for all of the CYP4F isoforms, and CYP4F6 had no detectable fatty acid -hydroxylase activity. The P450 -hydroxylase inhibitors 17-octadecynoic acid, 10-undecynyl sulfate, and N-methylsulfonyl-12,12-dibromododec-11-enamide showed isoform-specific inhibition of CYP4F1- and CYP4F4-catalyzed -hydroxylation of arachidonic acid and potency differences between the CYP4A and CYP4F isoforms. These data support a significant role for CYP4F1 and CYP4F4 in the formation of 20-HETE and identify P450 inhibitors that can be used to understand the relative contribution of the CYP4A and CYP4F isoforms to renal 20-HETE formation.
; Kikuta et al., 1993; Kawashima and Strobel, 1995; Cui et al., 2000, 2001; Bylund and Oliw, 2001; Hashizume et al., 2001). Four isoforms have been identified in the rat to date (Chen and Hardwick, 1993; Kawashima and Strobel, 1995). The first member of this family to be discovered was CYP4F1, a protein that is constitutively expressed at relatively high levels in rat hepatoma (Chen and Hardwick, 1993). Yeast-expressed CYP4F1 catalyzed the -hydroxylation of leukotriene B4 (LTB4), lipoxin A4, prostaglandin A1, and several hydroxyeicosatetraenoic acids (HETEs) (Kikuta et al., 1993). Rat CYP4F4, CYP4F5, and CYP4F6 were cloned from rat brain (Kawashima and Strobel, 1995). Escherichia coli-expressed CYP4F5 had low -hydroxylation activity toward LTB4, whereas the solubilized membrane fraction of CYP4F4 recombinant protein catalyzed the -hydroxylation of prostaglandin A1, prostaglandin E1, 6-trans-LTB4, and LTB4 (Kawashima and Strobel, 1995). More recently, yeast-expressed CYP4F5 was found to convert LTB4 primarily into 18-hydroxy-LTB4, and a relatively small amount of 19- and 17-hydroxy-LTB4 and yeast-expressed CYP4F6 was found to convert LTB4 into 19- and 18-hydroxy-LTB4 (Bylund et al., 2003). Neither CYP4F4 nor CYP4F1 was able to metabolize arachidonic acid or lauric acid, two typical substrates for CYP4A enzymes (Kawashima et al., 1997; Kikuta et al., 1999). Of the five human CYP4F isoforms identified to date, CYP4F2, CYP4F3, and CYP4F12 have all been shown to catalyze the -hydroxylation of arachidonic acid (Lasker et al., 2000; Christmas et al., 2001; Hashizume et al., 2001). Moreover, CYP4F2 is the major enzyme that catalyzes the -hydroxylation of arachidonic acid in human kidney microsomes (Lasker et al., 2000).
The -hydroxylation of arachidonic acid to form 20-HETE is of increasing interest due to the biological effects of 20-HETE on vascular tone and renal function. 20-HETE inhibits a large conductance, Ca2+-activated K+ channel (maxi K) in renal microvessels leading to potent vasoconstriction (Zou et al., 1996). In addition, 20-HETE is an endogenous inhibitor of Na+,K+-ATPase (Schwartzman et al., 1985), blocks a 70-pS potassium channel in the thick ascending limb of Henle's loop, and inhibits Na+-K+-2Cl– cotransport (Escalante et al., 1994; Wang and Lu, 1995). 20-HETE has also been implicated in the autoregulation of renal blood flow and tubuloglomerular feedback (Zou et al., 1994a,b). Alterations in renal 20-HETE production may contribute to the development of hypertension in both the spontaneously hypertensive rat and the Dahl salt-sensitive rat (Stec et al., 1996; Kroetz et al., 1997). Inhibition of renal 20-HETE formation with specific fatty acid -hydroxylase inhibitors or antisense oligonucleotides reduces blood pressure in the spontaneously hypertensive rat and angiotensin II models of hypertension (Su et al., 1998; Wang et al., 2001; Alonso-Galicia et al., 2002; Xu et al., 2002).
The biological functions of 20-HETE are largely characterized in the rat, and its renal formation is generally considered to be catalyzed by CYP4A enzymes (Nguyen et al., 1999; Hoch et al., 2000). However, the recent identification of CYP4F isoforms expressed in the rat kidney (Kalsotra et al., 2002; Bylund et al., 2003) and the finding that CYP4F2 is the major arachidonic acid -hydroxylase in human kidney (Lasker et al., 2000) led us to hypothesize that the CYP4F enzymes also contribute to renal 20-HETE formation in the rat. In the present study, the four rat CYP4F isoforms were heterologously expressed in E. coli, and their metabolism of fatty acids was characterized. The sensitivity of each of the CYP4F isoforms to known P450 inhibitors was also investigated.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
; Xu et al., 2002). Rat cytochrome P450 reductase was expressed and purified as previously reported (Dierks et al., 1998). Ampicillin, 
-aminolevulinic acid, glycerol, lysozyme, dilauroylphosphatidylcholine, catalase, and NADPH were obtained from Sigma-Aldrich. Emulgen 913 was from Karlan Research Products (Santa Rosa, CA). Acetonitrile (HPLC grade) and Scintiverse Cocktail LC were purchased from Fisher Scientific Co. (Fair Lawn, NJ).
E. Coli Expression of CYP4F Isoforms. The CYP4F1 cDNA was kindly provided by Dr. James P. Hardwick (Northeastern Ohio Universities College of Medicine), and the full-length cDNAs of CYP4F4 (1608 bp), CYP4F5 (1660 bp), and CYP4F6 (1707 bp) were isolated from Sprague-Dawley rat liver or kidney as described previously (LeBrun et al., 2002). The CYP4F1, CYP4F4, CYP4F5, and CYP4F6 hexahistidine-tagged proteins were expressed in DH5
cells, purified on a Ni2+-nitrilotriacetic acid agarose column from Qiagen (Valencia, CA), and desalted on a PD-10 column (Amersham Biosciences AB, Uppsala, Sweden) (LeBrun et al., 2002).
Spectroscopic Methods. Absolute spectra of rat CYP4F proteins were recorded on a Hewlett-Packard 8452 diode array spectrophotometer. Reduced CO-difference spectra and substrate perturbation analyses were done on a Varian Cary 1E UV/visible dual-beam spectrophotometer (Varian, Inc., Palo Alto, CA). Both instruments were equipped with a temperature control accessory. The P450 content was determined using the method of Omura and Sato (1964a). To obtain substrate binding-difference spectra, the fatty acids were dissolved in dimethyl sulfoxide and titrated into the different CYP4F solutions using a 10-µl Hamilton syringe, resulting in a final sample volume change of less than 1%. All spectra were obtained at 25°C. The spectral binding constant, Ks, was determined from the hyperbolic plot of the differences in the 420- to 390-nm peak to trough absorbance versus the substrate concentration.
Measurement of CYP4F Catalytic Activity. The activity of CYP4F in the metabolism of fatty acids was measured in a reaction mixture of 20 µg/ml dilauroylphosphatidylcholine, 0.2 mg/ml sodium cholate, 50 pmol/ml CYP4F, 500 pmol/ml cytochrome P450 reductase, 50 pmol/ml cytochrome b5, and 10 µg/ml catalase. This mixture was incubated for 10 min at room temperature before 100 mM potassium phosphate buffer, pH 7.4, containing 10 mM MgCl2, 8 mM sodium isocitrate, and 0.5 IU isocitrate dehydrogenase was added. LTB4 (100 µM), [1-14C]arachidonic acid (40 µM), or [1-14C]lauric acid (40 µM) was added to the incubation, and after a 3-min preincubation at 37°C, the reaction was initiated by the addition of NADPH to a final concentration of 1 mM. The final volume of the reaction was 0.1 ml. The reaction was stopped after 1 to 30 min by the addition of 1 N HCl to a final pH of 3 to 3.5. Metabolites were extracted with ethyl acetate and quantified by HPLC with UV or radiometric detection as described previously (Sumimoto et al., 1988; Kroetz et al., 1997; Su et al., 1998).
Effect of Inhibitors on CYP4F-Catalyzed Arachidonic Acid -Hydroxylation. Reconstituted CYP4F1 and CYP4F4 were incubated for 30 min at 37°C with 1 mM NADPH, an isocitrate dehydrogenase regenerating buffer as described above, and various concentrations of the known P450 inhibitors MS-PPOH, 17-ODYA, DDMS, 10-SUYS, or ABT. After inactivation, the proteins were diluted 10-fold, and arachidonic acid metabolism was measured as described above. IC50 values were estimated by fitting the data to the equation V = Vo / [1 + (I / IC50)n], where V is the 20-HETE formation rate in the presence of inhibitor, Vo is 20-HETE formation rate in the absence of inhibitor, I is the inhibitor concentration, and n is the Hill coefficient. The KaleidaGraph fitting program (Abelbeck/Synergy, Reading, PA) was used to fit the data by nonlinear regression.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
). After reaction with CO and reduction with sodium dithionite, all four proteins exhibited a strong absorption with a maximum at 450 nm, as expected for intact P450 (Fig. 1, E-H) (Omura and Sato, 1964b). CYP4F1, CYP4F5, and CYP4F6 were present as pure intact, thiolate-ligated P450 proteins. A minor cytochrome P420 shoulder was seen for CYP4F4, indicating this protein was present as a mixture of the active P450 protein and a denatured inactive protein in which the absorption maximum was at 420 nm. The proportion of the protein in the intact, active state in CYP4F4 was about 83%. The CYP4F4 protein has not previously been obtained in purified, active form (Kawashima et al., 1997).
|
The spectroscopic binding constants for LTB4, lauric acid, and arachidonic acid are summarized in Table 1. All the difference spectra were type I (Estabrook et al., 1972), indicating a net shift of the heme from the low to the high spin state. The spectral perturbation was characterized by a maximum at 390 nm, a trough with an absorbance minimum at 420 nm, and an apparent isosbestic point at 407 nm (Fig. 2). No perturbation was observed when lauric acid was titrated into CYP4F1 or when all three substrates were titrated into CYP4F5 and CYP4F6, suggesting that these fatty acids were bound very poorly or, when bound, did not induce a spin state change of the iron atom. In general, arachidonic acid and LTB4 had similar binding affinity to CYP4F1 and CYP4F4. Lauric acid bound CYP4F4 but not CYP4F1. In contrast, arachidonic acid and lauric acid had higher binding affinity to CYP4A isoforms than CYP4F isoforms (Hoch et al., 2000).
|
|
Fatty Acid Metabolism by CYP4F Isoforms. To establish optimal conditions for determination of CYP4F catalytic activity, the effects of varying amounts of NADPH P450 reductase and cytochrome b5 on arachidonic acid hydroxylation were measured. CYP4F1 and CYP4F4 had catalytic activity toward arachidonic acid in the absence of cytochrome b5, but an equimolar amount of cytochrome b5 and a 2- to 10-fold excess of NADPH P450 reductase were needed for maximal catalytic activity of both enzymes (data not shown). Based on these preliminary studies, 50 pmol/ml of purified enzyme and a 1:10:1 ratio of CYP4F/cytochrome P450 reductase/cytochrome b5 were chosen to characterize the activity of rat CYP4F isoforms in the metabolism of fatty acids.
CYP4F enzymes have been characterized as LTB4 -hydroxylases (Kawashima et al., 1997; Kikuta et al., 1999), so this substrate was used as a positive control to test the catalytic activity of the expressed rat CYP4F isoforms. Recombinant CYP4F1, CYP4F4, and CYP4F5 proteins all catalyzed the metabolism of LTB4, whereas CYP4F6 had no detectable activity (Fig. 3). CYP4F4 had the highest LTB4 -hydroxylase activity with a Km and Vmax of 31 µM and 40 nmol/min/nmol, respectively, followed by CYP4F1 with a Km and Vmax of 24 µM and 10 nmol/min/nmol, respectively (Fig. 4). CYP4F5 had only minor activity toward LTB4, and the kinetic parameters were not measurable.
|
|
Figure 5 shows a representative HPLC chromatogram of arachidonic acid metabolites formed after incubation with the expressed rat CYP4F isoforms. CYP4F1 and CYP4F4 -hydroxylated arachidonic acid to form 20-HETE, the major metabolite detected. Both enzymes also formed minor amounts of the -1 hydroxylation product, 19-HETE (Fig. 5, A and B). The relative ratios of the - and -1 hydroxylated metabolites were 21:1 for CYP4F1 and 20:1 for CYP4F4, indicating a strong preference for oxidation at the -position of arachidonic acid. In contrast, CYP4F5 and CYP4F6 had no detectable catalytic activity toward arachidonic acid despite modification of the reconstitution and incubation conditions (Fig. 5, C and D).
|
The kinetics describing arachidonic acid metabolism by CYP4F1 and CYP4F4 were investigated, and the concentration-dependent activity is shown in Fig. 6. Increasing -hydroxylase activities were measured with increasing arachidonic acid concentrations up to 40 µM. Further increases in the concentration of arachidonic acid resulted in a gradual drop in activity. This decrease in activity may be caused by substrate or product inhibition, by micellar aggregation of the fatty acids, or by physical effects of the fatty acids on the reconstituted enzyme. It has previously been suggested that the detergent activity of long-chain fatty acids may disturb the arrangement of the electron transfer partners in the reconstituted system (Hoch et al., 2000).
|
The catalytic activities of the CYP4F proteins with fatty acids were further characterized by measuring apparent kcat values. CYP4F4 had the highest activity in the metabolism of arachidonate, laurate, and LTB4 (Table 2). LTB4 was the best substrate for CYP4F4, whereas arachidonic acid was the best substrate for CYP4F1. Arachidonic acid was a much better substrate for CYP4F1 and CYP4F4 than lauric acid. In contrast, CYP4A1, CYP4A2, CYP4A3, and CYP4A8 all catalyze the - and -1-hydroxylation of arachidonic acid and lauric acid, with the latter being the preferred substrate (Nguyen et al., 1999; Hoch et al., 2000). CYP4F1 and CYP4F4 had similar arachidonic acid -hydroxylase activity as CYP4A1, the most active CYP4A isoform with an apparent kcat of 6 min–1 (Hoch et al., 2000).
|
Lauric acid, although not physiologically significant, has been used as a prototype substrate for the CYP4A proteins and was investigated here as a substrate for the rat CYP4F isoforms. Only CYP4F4 had minor lauric acid hydroxylase activity (Fig. 7 and Table 2). The relative ratio of the - and (-1)-hydroxylated metabolites was 5:1.
|
Effect of Inhibitors on Recombinant CYP4F-Catalyzed Arachidonic Acid -Hydroxylation. Numerous inhibitors of arachidonic acid -hydroxylation and epoxidation have been characterized for their activity against the CYP4A isoforms, but their effects on the CYP4F enzymes have not been reported. The terminal acetylenic compound MS-PPOH selectively inhibited microsomal arachidonic acid epoxidation (Wang et al., 1998), and the addition of MS-PPOH (1–500 µM) had no effect on CYP4F1- and CYP4F4-mediated -hydroxylation of arachidonic acid (Table 3). Both -hydroxylation and epoxidation of arachidonic acid by Sf9-expressed CYP4A isoforms are inhibited by 17-ODYA, a widely used acetylenic inhibitor of fatty acid metabolism (Zou et al., 1994c; Nguyen et al., 1999). 17-ODYA also potently inhibited the CYP4F1- and CYP4F4-mediated -hydroxylation of arachidonic acid with an IC50 of 1.81 and 5.59 µM, respectively (Table 3 and Fig. 8A). DDMS, a specific inhibitor of microsomal arachidonic acid -hydroxylation, potently decreased - and -1-hydroxylation and epoxidation catalyzed by CYP4A1, CYP4A2, and CYP4A3, with a similar IC50 for all isoforms (Wang et al., 1998). In contrast, it had no effect on CYP4F1-mediated -hydroxylation of arachidonic acid and only slightly inhibited CYP4F4-mediated 20-HETE formation with an IC50 of 145 µM (Table 3). 10-SUYS, a specific inhibitor of microsomal arachidonic acid -hydroxylation (Xu et al., 2002), inhibited the arachidonic acid -hydroxylase activity of CYP4F1 and CYP4F4 with an IC50 of 231 and 25.0 µM, respectively (Table 3 and Fig. 8B). ABT has been characterized as a specific inhibitor of microsomal arachidonic acid -hydroxylation (Su et al., 1998), and it inhibited the CYP4F1- and CYP4F4-mediated -hydroxylation of arachidonic acid with an IC50 of 289 and 371 µM, respectively (Table 3 and Fig. 8C). With the exception of ABT, CYP4F1 and CYP4F4 showed different sensitivity to the P450 -hydroxylase inhibitors tested (Table 3 and Fig. 8).
|
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
-hydroxylation of arachidonic acid to form 20-HETE has generally been attributed to the CYP4A isoforms (Nguyen et al., 1999; Hoch et al., 2000). More recently, members of the CYP4F family have been cloned and characterized with respect to their catalytic function, tissue expression, and transcriptional regulation (Chen and Hardwick, 1993; Kawashima and Strobel, 1995; Kawashima et al., 1997; Kikuta et al., 1999; Cui et al., 2000, 2001; Zhang et al., 2000). Much of the interest in the CYP4F enzymes has focused on their role in the -hydroxylation of LTB4, an important step in controlling the potent inflammatory properties of this eicosanoid (Sumimoto et al., 1988). In contrast, little is known about the ability of the CYP4F proteins to catalyze arachidonic acid metabolism. Although the rat CYP4F isoforms have been heterologously expressed in both yeast and E. coli (Kawashima et al., 1997; Kikuta et al., 1999; Bylund et al., 2003), this represents the first study in which the catalytic function of all four rat isoforms has been directly compared. Despite more than 70% amino acid sequence identity, the rat CYP4F isoforms show differences in substrate specificity and sensitivity to known P450 inhibitors.
Both human and rat CYP4Fs have been characterized as LTB4 -hydroxylases (Kikuta et al., 1993, 1999; Kawashima et al., 1997). The current study suggests that the majority of the LTB4 -hydroxylase activity in the rat is catalyzed by CYP4F1 and CYP4F4. The Km for CYP4F1 in the present study (24 µM) is much lower than that reported for CYP4F1 expressed in yeast (134 µM; Kikuta et al., 1999), possibly due to the different expression systems and incubation conditions. The activity of CYP4F4 was also much higher than that reported previously for an E. coli-expressed cell lysate (Kawashima et al., 1997). Despite repeated attempts to optimize the reconstitution and incubation conditions for CYP4F5 and CYP4F6, metabolism of LTB4 was difficult to detect. Minor activity was detected with CYP4F5, whereas CYP4F6 was devoid of LTB4 -hydroxylase activity. These results are in conflict with the extensive side-chain hydroxylation of LTB4 reported for yeast-expressed CYP4F5 and CYP4F6 (Bylund et al., 2003). Although CYP4F1 and CYP4F4 are clearly implicated in the metabolism of LTB4 and regulation of inflammation, further studies will be necessary to clarify the role of CYP4F5 and CYP4F6 in this pathway.
A direct comparison of the arachidonic acid -hydroxylase activity of all four rat CYP4F isoforms identified CYP4F1 and CYP4F4 as major catalysts of 20-HETE formation. In fact, the kcat values for CYP4F1 and CYP4F4 were very similar to those reported previously for the most active CYP4A isoform, CYP4A1 (Hoch et al., 2000). This is consistent with the identification of CYP4F2 as the major arachidonic acid -hydroxylase in human liver (Lasker et al., 2000). However, the inability of yeast-expressed CYP4F1 (Kikuta et al., 1999) and E. coli-expressed CYP4F4 (Kawashima et al., 1997) to metabolize arachidonic or lauric acid highlights the importance of determining optimal conditions for reconstitution of P450 activity with expressed proteins. Although the relative importance of the CYP4A and CYP4F isoforms in 20-HETE formation within rat tissues is still unclear, these results support a potential role for both enzyme families in this catalytic function.
A major difference in the activity of the CYP4A and CYP4F isoforms is reflected in the inability of most of the latter enzymes to metabolize lauric acid. CYP4A isoforms readily catalyze the -hydroxylation of lauric acid, which is the prototypical substrate for this subfamily (Nguyen et al., 1999; Hoch et al., 2000). Elongation of the fatty acid chain is associated with a loss of CYP4A -hydroxylase activity (Hoch et al., 2000). Although further studies will be necessary to determine the influence of hydrocarbon chain length on the activity of the CYP4F enzymes, these results establish distinct substrate specificity between the CYP4A and CYP4F subfamilies.
The identification of CYP4F1 and CYP4F4 as arachidonic acid -hydroxylases and their detection in rat kidney (Kalsotra et al., 2002) implicates them in the renal formation of 20-HETE. CYP4F1 accounts for 95% of total CYP4F expression in the Sprague-Dawley kidney, whereas CYP4F4 has the lowest expression (less than 0.01% of total CYP4F expression) (Kalsotra et al., 2002). The abundant expression of CYP4F1 in the rat kidney and our finding that CYP4F1 has similar arachidonic acid -hydroxylase activity to the most active CYP4A isoform, CYP4A1, suggests that CYP4F1 is the major CYP4F isoform that contributes to renal 20-HETE biosynthesis in the kidney. Relatively little is known about the regulation of the renal CYP4F enzymes. Clofibrate treatment decreased CYP4F1, CYP4F5, and CYP4F6 and had no effect on CYP4F4 mRNA levels in rat liver (Kalsotra et al., 2002). Although tissue-specific differences in response to fibric acids make it difficult to predict the effect of this classic inducer on renal CY4F levels, it is interesting to note that in the liver, CYP4F1 is repressed, whereas CYP4A1 is induced by clofibrate. This suggests that the increased 20-HETE formation expected from CYP4A1 induction by clofibrate may be somewhat balanced by the decrease in 20-HETE formation due to CYP4F1 repression. Renal CYP4F expression was also reported to be higher in females relative to males and to be regulated by estrogen. This is in contrast to CYP4A expression, which is higher in males than females. This would support a differential role for the CYP4F and CYP4A isoforms in 20-HETE formation in males and females. Interestingly, Kalsotra et al. (2002) also reported that the expression level of lung CYP4F4 can be induced up to 10-fold 24 h after traumatic brain injury. Our results indicate that CYP4F4 has higher arachidonic acid -hydroxylase activity than CYP4F1, but its low expression in kidney does not support a major role for this isoform in renal 20-HETE formation. It will be interesting to examine whether CYP4F4 plays its major role in 20-HETE biosynthesis in other tissues during such conditions as traumatic brain injury.
The potent vasoconstrictor effect of 20-HETE on renal arteries is considered prohypertensive, whereas its natriuretic and diuretic effects in renal tubules would contribute to a lowering of blood pressure. The relative importance of the CYP4F and CYP4A isoforms to renal 20-HETE formation will be a function of their expression pattern within the renal tubules and microvessels as well as the catalytic function of each enzyme. CYP4A and CYP4F mRNAs are expressed in a segment- and gender-specific pattern in the mouse kidney (Stec et al., 2003). Characterization of the corresponding expression pattern in the rat kidney will provide important information about the relative contribution of each of the CYP4F and CYP4A isoforms to renal 20-HETE formation.
P450 inhibitors are an important tool in characterizing the biological significance of 20-HETE. CYP4F1 and CYP4F4 displayed different sensitivity to several inhibitors of P450 -hydroxylase activity. Surprisingly, DDMS, a very potent inhibitor of CYP4A-catalyzed arachidonic acid -hydroxylation and epoxidation (Nguyen et al., 1999), had minimal effect on CYP4F1- or CYP4F4-catalyzed 20-HETE formation. 10-SUYS, a specific inhibitor of microsomal arachidonic acid -hydroxylation (Xu et al., 2002), was a relatively potent inhibitor of CYP4F4 but had only a minor effect on CYP4F1. This suggests that 10-SUYS can be used at low concentrations to selectively inhibit CYP4F4 fatty acid -hydroxylase activity and that DDMS can be used to selectively inhibit CYP4A but not CYP4F arachidonic acid -hydroxylase activity. In contrast, 17-ODYA and ABT showed similar effects on CYP4F1 or CYP4F4, consistent with their relatively nonspecific inhibition of arachidonic acid hydroxylation and epoxidation (Wang et al., 1998; Nguyen et al., 1999; Alonso-Galicia et al., 2002). The isoform selectivity observed in this study is consistent with the incomplete inhibition of arachidonic acid -hydroxylation observed with many P450 inhibitors when used in microsomal systems. The identification of isoform specific inhibitors such as 10-SUYS and DDMS will be invaluable for characterizing the relative contribution of a given CYP4A and/or CYP4F enzyme to 20-HETE formation.
In summary, CYP4F1 and CYP4F4 have been identified as arachidonic acid -hydroxylases. In light of the abundant expression of CYP4F1 in the rat kidney (Kalsotra et al., 2002), CYP4F1 may be a major contributor to the biosynthesis of 20-HETE in the rat kidney. Characterization of isoform-selective inhibition of arachidonic acid -hydroxylation supports the development of novel P450 inhibitors for wide-spread use in the in vivo and in vitro characterization of the biological properties of 20-HETE.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
ABBREVIATIONS: P450, cytochrome P450; LTB4, leukotriene B4; HETE, hydroxyeicosatetraenoic acid; MS-PPOH, N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanoic acid; DDMS, N-methylsulfonyl-12,12-dibromododec-11-enamide; 17-ODYA, 17-octadecynoic acid; 10-SUYS, sodium 10-undecynyl sulfate; ABT, 1-aminobenzotriazole; HPLC, high-performance liquid chromatography; bp, base pair(s).
Address correspondence to: Dr. Deanna L. Kroetz, Department of Biopharmaceutical Sciences, 513 Parnassus, Box 0446, San Francisco, CA 94143-0446. E-mail: deanna{at}itsa.ucsf.edu
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Alonso-Galicia M, Maier KG, Greene AG, Cowley AW, and Roman RJ (2002) Role of 20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor actions of angiotensin II. Am J Physiol 283: R60–R68.
Bylund J, Harder AG, Maier KG, Roman RJ, and Harder DR (2003) Leukotriene B4 -side chain hydroxylation by CYP4F5 and CYP4F6. Arch Biochem Biophys 412: 34–41.[CrossRef][Medline]
Bylund J and Oliw EH (2001) Cloning and characterization of CYP4F21: a prostaglandin E2 20-hydroxylase of ram seminal vesicles. Arch Biochem Biophys 389: 123–129.[CrossRef][Medline]
Chen L and Hardwick JP (1993) Identification of a new P450 subfamily, CYP4F1, expressed in rat hepatic tumors. Arch Biochem Biophys 300: 18–23.[CrossRef][Medline]
Christmas P, Jones JP, Patten CJ, Rock DA, Zheng Y, Cheng SM, Weber BM, Carlesso N, Scadden DT, Rettie AE, et al. (2001) Alternative splicing determines the function of CYP4F3 by switching substrate specificity. J Biol Chem 276: 38166–38172.
Cui X, Kawashima H, Barclay TB, Peters JM, Gonzalez FJ, Morgan ET, and Strobel HW (2001) Molecular cloning and regulation of expression of two novel mouse CYP4F genes: expression in peroxisome proliferator-activated receptor -deficient mice upon lipopolysaccharide and clofibrate challenges. J Pharmacol Exp Ther 296: 542–550.
Cui X, Nelson DR, and Strobel HW (2000) A novel human cytochrome P450 4F isoform (CYP4F11): cDNA cloning, expression and genomic structural characterization. Genomics 68: 161–166.[CrossRef][Medline]
Dawson JH and Sono M (1987) Cytochrome P-450 and chloroperoxidase: thiolateligated heme enzymes. Spectroscopic determination of their active-site structures and mechanistic implications of thiolate ligation. Chem Rev 87: 1255–1276.[CrossRef]
Dierks EA, Davis SC, and Ortiz de Montellano PR (1998) Glu-320 and Asp-323 are determinants of the CYP4A1 hydroxylation regiospecificity and resistance to inactivation by 1-aminobenzotriazole. Biochemistry 37: 1839–1847.[CrossRef][Medline]
Escalante B, Erlij D, Falck JR, and McGiff JC (1994) Cytochrome P-450 arachidonate metabolites affect ion fluxes in rabbit medullary thick ascending limb. Am J Physiol 266: C1775–C1782.
Estabrook RW, Peterson J, Baron J, and Hildebrandt A (1972) The spectrophotometric measurement of turbid suspensions of cytochromes associated with drug metabolism, in Methods in Pharmacology (Chignell CF ed) pp 303–350, Appleton-Century Crofts, New York.
Falck JR, Belosludtsev YY, Reddy KK, Reddy KM, Shortt MF, Chauhan K, Capdevila JH, and Wei S (1997) Eicosanoid biosynthesis: differential inhibition of cytochrome P450 epoxygenase and -hydroxylase. Bioorg Med Chem Lett 7: 3053–3056.[CrossRef]
Hashizume T, Imaoka S, Hiroi T, Terauchi Y, Fujii T, Miyazaki H, Kamataki T, and Funae Y (2001) cDNA cloning and expression of a novel cytochrome P450 (CYP4F12) from human small intestine. Biochem Biophys Res Commun 280: 1135–1141.[CrossRef][Medline]
Hoch U, Zhang Z, Kroetz DL, and Ortiz de Montellano PR (2000) Structural determination of the substrate specificities and regioselectivities of the rat and human fatty acid -hydroxylases. Arch Biochem Biophys 373: 63–71.[CrossRef][Medline]
Kalsotra A, Anakk S, Boehme CL, and Strobel HW (2002) Sexual dimorphism and tissue specificity in the expression of CYP4F forms in Sprague Dawley rats. Drug Metab Dispos 30: 1022–1028.
Kawashima H, Kusunose E, Thompson CM, and Strobel HW (1997) Protein expression, characterization and regulation of CYP4F4 and CYP4F5 cloned from rat brain. Arch Biochem Biophys 347: 148–154.[CrossRef][Medline]
Kawashima H and Strobel HW (1995) cDNA cloning of three new forms of rat brain cytochrome P450 belonging to the CYP4F subfamily. Biochem Biophys Res Commun 217: 1137–1144.[CrossRef][Medline]
Kikuta Y, Kusunose E, Endo K, Yamamoto S, Sogawa K, Fujii-Kuriyama Y, and Kusunose M (1993) A novel form of cytochrome P-450 family 4 in human polymorphonuclear leukocytes. cDNA cloning and expression of leukotriene B4 -hydroxylase. J Biol Chem 268: 9376–9380.
Kikuta Y, Kusunose E, Ito M, and Kusunose M (1999) Purification and characterization of recombinant rat hepatic CYP4F1. Arch Biochem Biophys 369: 193–196.[CrossRef][Medline]
Kroetz DL, Huse LM, Thuresson A, and Grillo MP (1997) Developmentally regulated expression of the CYP4A genes in the spontaneously hypertensive rat kidney. Mol Pharmacol 52: 362–372.
Lasker JM, Chen WB, Wolf I, Bloswick BP, Wilson PD, and Powell PK (2000) Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of CYP4F2 and CYP4A11. J Biol Chem 275: 4118–4126.
LeBrun LA, Xu F, Kroetz DL, and Ortiz de Montellano PR (2002) Covalent attachment of the heme prosthetic group in the CYP4F cytochrome P450 family. Biochemistry 41: 5931–5937.[CrossRef][Medline]
Nguyen X, Wang MH, Reddy KM, Falck JR, and Schwartzman ML (1999) Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific inhibitors. Am J Physiol 276: R1691–R1700.
Okita RT, Clark JE, Okita JR, and Masters BS (1991) - and (-1)-hydroxylation of eicosanoids and fatty acids by high-performance liquid chromatography. Methods Enzymol 206: 432–441.[Medline]
Omura T and Sato R (1964a) The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 239: 2379–2385.
Omura T and Sato R (1964b) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239: 2370–2378.
Schwartzman M, Ferreri NR, Carroll MA, Songu-Mize E, and McGiff JC (1985) Renal cytochrome P450-related arachidonate metabolite inhibits Na+,K+-ATPase. Nature (Lond) 314: 620–622.[CrossRef][Medline]
Stec DE, Deng AY, Rapp JP, and Roman RJ (1996) Cytochrome P4504A genotype cosegregates with hypertension in Dahl S rats. Hypertension 27: 564–568.
Stec DE, Flasch A, Roman RJ, and White JA (2003) Distribution of cytochrome P-450 4A and 4F isoforms along the nephron in mice. Am J Physiol 284: F95–F102.
Su P, Kaushal KM, and Kroetz DL (1998) Inhibition of renal arachidonic acid -hydroxylase activity with ABT reduces blood pressure in the SHR. Am J Physiol 275: R426–R438.
Sumimoto J, Takeshige K, and Minakami S (1988) Characterization of human neutrophil leukotriene B4 -hydroxylase as a system involving a unique cytochrome P-450 and NADPH-cytochrome P-450 reductase. Eur J Biochem 172: 315–324.[Medline]
Wang MH, Brand-Schieber E, Zand BA, Nguyen X, Falck JR, Balu N, and Schwartzman ML (1998) Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J Pharmacol Exp Ther 284: 966–973.
Wang MH, Zhang F, Marji J, Zand BA, Nasjletti A, and Laniado-Schwartzman M (2001) CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SHR. Am J Physiol 280: R255–R261.
Wang W and Lu M (1995) Effect of arachidonic acid on activity of the apical K+ channel in the thick ascending limb of the rat kidney. J Gen Physiol 106: 727–743.
Xu F, Straub WO, Pak W, Su P, Maier KG, Yu M, Roman RJ, Ortiz De Montellano PR, and Kroetz DL (2002) Antihypertensive effect of mechanism-based inhibition of renal arachidonic acid -hydroxylase activity. Am J Physiol 283: R710–R720.
Zhang X, Chen L, and Hardwick JP (2000) Promoter activity and regulation of the CYP4F2 leukotriene B4 -hydroxylase gene by peroxisomal proliferators and retinoic acid in HepG2 cells. Arch Biochem Biophys 378: 364–376.[CrossRef][Medline]
Zou AP, Fleming JT, Falck JR, Jacobs ER, Gebremedhin D, Harder DR, and Roman RJ (1996) 20-HETE is an endogenous inhibitor of the large-conductance Ca2+-activated K+ channel in renal arterioles. Am J Physiol 270: R228–R237.
Zou AP, Imig JD, Kaldunski M, Ortiz de Montellano PR, Sui Z, and Roman RJ (1994a) Inhibition of renal vascular 20-HETE production impairs autoregulation of renal blood flow. Am J Physiol 266: F275–F282.
Zou AP, Imig JD, Ortiz de Montellano PR, Sui Z, Falck JR, and Roman RJ (1994b) Effect of P-450 -hydroxylase metabolites of arachidonic acid on tubuloglomerular feedback. Am J Physiol 266: F934–F941.
Zou AP, Ma YH, Sui ZH, Ortiz de Montellano PR, Clark JE, Masters BS, and Roman RJ (1994c) Effects of 17-octadecynoic acid, a suicide-substrate inhibitor of cytochrome P450 fatty acid -hydroxylase, on renal function in rats. J Pharmacol Exp Ther 268: 474–481.
This article has been cited by other articles:
|
|
 |
|
  M. Fer, L. Corcos, Y. Dreano, E. Plee-Gautier, J.-P. Salaun, F. Berthou, and Y. Amet Cytochromes P450 from family 4 are the main omega hydroxylating enzymes in humans: CYP4F3B is the prominent player in PUFA metabolism J. Lipid Res., November 1, 2008; 49(11): 2379 - 2389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.-J. Sanders, R. Ofman, G. Dacremont, R. J. A. Wanders, and S. Kemp Characterization of the human {omega}-oxidation pathway for {omega}-hydroxy-very-long-chain fatty acids FASEB J, June 1, 2008; 22(6): 2064 - 2071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dhar, D. W. Sepkovic, V. Hirani, R. P. Magnusson, and J. M. Lasker Omega oxidation of 3-hydroxy fatty acids by the human CYP4F gene subfamily enzyme CYP4F11 J. Lipid Res., March 1, 2008; 49(3): 612 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Z. Wang, J. Q. Wu, A. S. Bridges, D. C. Zeldin, S. Kornbluth, R. R. Tidwell, J. E. Hall, and M. F. Paine Human Enteric Microsomal CYP4F Enzymes O-Demethylate the Antiparasitic Prodrug Pafuramidine Drug Metab. Dispos., November 1, 2007; 35(11): 2067 - 2075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Y. Ng, Y. Huang, L. M. Reddy, J. R. Falck, E. T. Lin, and D. L. Kroetz Cytochrome P450 Eicosanoids are Activators of Peroxisome Proliferator-Activated Receptor {alpha} Drug Metab. Dispos., July 1, 2007; 35(7): 1126 - 1134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Singh, J. Cheng, H. Deng, R. Kemp, T. Ishizuka, A. Nasjletti, and M. L. Schwartzman Vascular Cytochrome P450 4A Expression and 20-Hydroxyeicosatetraenoic Acid Synthesis Contribute to Endothelial Dysfunction in Androgen-Induced Hypertension Hypertension, July 1, 2007; 50(1): 123 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Xu, V. Y. Ng, D. L. Kroetz, and P. R. O. de Montellano CYP4 Isoform Specificity in the {omega}-Hydroxylation of Phytanic Acid, a Potential Route to Elimination of the Causative Agent of Refsum's Disease J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 835 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.-J. Sanders, R. Ofman, M. Duran, S. Kemp, and R. J. A. Wanders {omega}-Oxidation of Very Long-chain Fatty Acids in Human Liver Microsomes: IMPLICATIONS FOR X-LINKED ADRENOLEUKODYSTROPHY J. Biol. Chem., May 12, 2006; 281(19): 13180 - 13187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Yu, V. Y. Ng, P. Su, M. M. Engler, M. B. Engler, Y. Huang, E. Lin, and D. L. Kroetz Induction of Renal Cytochrome P450 Arachidonic Acid Epoxygenase Activity by Dietary {gamma}-Linolenic Acid J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 732 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.-J. Sanders, R. Ofman, F. Valianpour, S. Kemp, and R. J. A. Wanders Evidence for two enzymatic pathways for {omega}-oxidation of docosanoic acid in rat liver microsomes J. Lipid Res., May 1, 2005; 46(5): 1001 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Poloyac, M. A. Tortorici, D. I. Przychodzin, R. B. Reynolds, W. Xie, R. F. Frye, and M. A. Zemaitis THE EFFECT OF ISONIAZID ON CYP2E1- AND CYP4A-MEDIATED HYDROXYLATION OF ARACHIDONIC ACID IN THE RAT LIVER AND KIDNEY Drug Metab. Dispos., July 1, 2004; 32(7): 727 - 733. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
) and CYP4F4 (
) were incubated with varying concentrations of LTB4, and the 
